Global Opioid-Induced Constipation Market Report 2015-2019 - Shift to Targeted Therapy with AstraZeneca, Takeda Pharmaceutical & Valeant Pharmaceuticals International Dominating
DUBLIN, July 17, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/3wm87k/global) has announced the addition of the "Global Opioid-Induced Constipation Market 2015-2019" report to their offering.
The global opioid-induced constipation market to grow at a CAGR of 30.18% over the period 2014-2019.
This report covers the present scenario and the growth prospects of the global opioid-induced constipation market for 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of opioid-induced constipation, which includes branded drugs, off-label products, and OTC drugs.
Some of the common symptoms of opioid-induced constipation are hard and dry stools, painful defecation, bloating, distention and bulged abdomen, feeling lethargic, and loss of appetite. Opioid-induced constipation can be managed by changing lifestyle along with the use of targeted therapies and other OTC and off-label drugs.
The market was served by various off-label and OTC therapies to treat the condition. However, in 2008, Relistor, a targeted therapy for treating opioid-induced constipation, was approved by the US FDA and the EMA. This drug is a peripherally acting mu-opioid receptor antagonist and was the first targeted therapy to obtain approval for this indication. Movantik/Moventig, also a peripherally acting mu-opioid receptor antagonist, was approved by the US FDA and the EMA in 2014 and is a targeted therapy for this indication. These drugs reduce the undesirable effects of the opioid analgesics without affecting its analgesic effects. Therefore, these drugs are increasingly becoming the preferred medication to treat opioid-induced constipation.
According to the report, the low levels of awareness about opioid-induced constipation among patients and the medical fraternity have resulted in the usage of off-label and OTC medications as the treatment options. However, these drugs are only partially successful in treating this condition. The entry of peripherally acting mu-opioid receptor antagonists such as Movantik/Moventig has driven the market significantly. The drug targets the underlying cause of opioid-induced constipation without affecting the analgesic action of the opioid drugs. Therefore, this is increasingly becoming the preferred treatment option for opioid-induced constipation.
Further, the report states that the availability of OTC and off-label drugs restricts the market growth.
On the basis of the mechanism of action of drugs, the market is grouped into the following categories:
- Peripherally Acting Mu-opioid Receptor Antagonist
- Locally Acting Chloride Channel Activator
- Others
On the basis of the route of administration of drugs, the market is grouped into the following categories:
- Oral
- Parenteral
On the basis of the dosage form of drugs, the market is grouped into the following categories:
- Solid
- Liquid
Key Vendors
- AstraZeneca
- Takeda Pharmaceutical
- Valeant Pharmaceuticals International
Other Prominent Vendors
- Abbott
- Bayer
- Boehringer Ingelheim
- C.B. Fleet
- Cosmo Pharmaceuticals
- Daewoong
- Daiichi Sankyo
- GlaxoSmithKline
- Ironwood Pharmaceuticals
- Johnson & Johnson
- Merck
- Mundipharma
- Nektar Therapeutics
- Pfizer
- Progenics Pharmaceuticals
- Shionogi
- SLA Pharma
- Sucampo
- Synergy Pharmaceuticals
- Theravance
For more information visit http://www.researchandmarkets.com/research/3wm87k/global
Media Contact:
Laura Wood, +353-1-481-1716, press@researchandmarkets.net
Share this article